

Supplemental Table 1. Distribution of lipids and non-cholesterol sterol levels by baseline campesterol/TC quartiles

Characteristics	Campesterol/TC quartiles				p
	Q1 N= 148	Q2 N= 147	Q3 N= 149	Q4 N= 147	
Age, years	46.6 ± 9.3	46.9 ± 8.8	44.3 ± 9.0	46.1 ± 9.6	P=0.074
Male sex, n (%)	60 (40.5)	78 (53.1)	85 (57.0)	83 (56.5)	P= 0.014
BMI, kg/m ²	29.0 ± 5.1	27.8 ± 4.5	26.5 ± 4.1	25.7 ± 3.5	P<0.001
Total cholesterol, mmol/l	10.1 ± 1.78	10.50 ± 1.90	10.12 ± 1.74	10.62 ± 1.91	P=0.032
LDL cholesterol, mmol/l	7.96 ± 1.75	8.36 ± 1.84	8.05 ± 1.63	8.59 ± 1.81	P=0.007
HDL cholesterol, mmol/l	1.19 ± 0.30	1.17 ± 0.27	1.21 ± 0.31	1.22 ± 0.30	P=0.487
Triglycerides, mmol/l	2.18 ± 1.09	2.19 ± 1.05	1.96 ± 1.18	1.83 ± 0.97	P=0.002
Sitosterol, mg/dl	0.33 ± 0.10	0.48 ± 0.13	0.56 ± 0.15	0.85 ± 0.28	P<0.001
Campesterol, mg/dl	0.40 ± 0.11	0.62 ± 0.13	0.81 ± 0.16	1.32 ± 0.46	P<0.001
Lathosterol, mg/dl	0.54 ± 0.20	0.54 ± 0.21	0.54 ± 0.24	0.48 ± 0.17	P=0.049
Sitosterol/TC ratio, µg/mg	0.84 ± 0.22	1.18 ± 0.26	1.44 ± 0.33	2.08 ± 0.59	P<0.001
Campesterol/TC ratio, µg/mg	1.01 ± 0.22	1.54 ± 0.13	2.08 ± 0.19	3.22 ± 0.90	P<0.001
Lathosterol/TC ratio, µg/mg	1.41 ± 0.51	1.33 ± 0.47	1.36 ± 0.55	1.19 ± 0.41	P<0.001
Simvastatin 80mg, N=289	N=82	N=70	N=68	N=69	
Change in LDL-C, mmol/l	-2.86 ± 1.06	-3.31 ± 1.45	-3.66 ± 1.59	-3.90 ± 1.56	p=0.420 ^a
Ezetimibe/simvastatin 10/80mg, N=302	N=66	N=77	N=81	N=78	
Change in LDL-C, mmol/l	-4.19 ± 1.05	-4.56 ± 1.42	-5.00 ± 1.23	-5.39 ± 1.70	p=0.535 ^a

Data are presented as mean ± SD, median [range] or number (%) per quartile. P indicates P for linearity between campesterol/TC quartiles and study parameters.

Associations of quartiles with baseline parameters were evaluated by means of ANOVA.

Associations of quartiles in the different treatment arms were evaluated by means of linear regression, ^a adjusted for baseline LDL-C

Supplemental Table 2. Distribution of lipids and non-cholesterol sterol levels by baseline lathosterol/TC quartiles

Characteristics	Lathosterol/TC quartiles				p
	Q1 N= 148	Q2 N=147	Q3 N= 148	Q4 N=148	
Age, years	46.2 ± 9.4	45.4 ± 9.3	46.6 ± 9.1	45.6 ± 9.2	P=0.665
Male sex, n (%)	63 (42.6)	75 (51.0)	80 (54.1)	88 (59.5)	P= 0.031
BMI, kg/m ²	25.01 ± 3.6	26.8 ± 4.4	27.8 ± 4.0	29.3 ± 4.8	P<0.001
Total cholesterol, mmol/l	10.49 ± 1.87	10.44 ± 1.86	10.36 ± 1.83	10.06 ± 1.80	P=0.185
LDL cholesterol, mmol/l	8.47 ± 1.79	8.36 ± 1.79	8.27 ± 1.71	7.85 ± 1.76	P=0.015
HDL cholesterol, mmol/l	1.27 ± 0.30	1.23 ± 0.29	1.18 ± 0.28	1.11 ± 0.30	P<0.001
Triglycerides, mmol/l	1.70 ± 0.95	1.87 ± 0.92	2.03 ± 1.02	2.54 ± 1.24	P<0.001
Sitosterol, mg/dl	0.64 ± 0.30	0.58 ± 0.26	0.54 ± 0.22	0.46 ± 0.22	P<0.001
Campesterol, mg/dl	0.87 ± 0.51	0.83 ± 0.45	0.78 ± 0.37	0.67 ± 0.33	P<0.001
Lathosterol, mg/dl	0.31 ± 0.09	0.45 ± 0.08	0.57 ± 0.11	0.77 ± 0.18	P<0.001
Sitosterol/TC ratio, µg/mg	1.58 ± 0.65	1.44 ± 0.60	1.35 ± 0.54	1.16 ± 0.49	P<0.001
Campesterol/TC ratio, µg/mg	2.14 ± 1.08	2.05 ± 0.98	1.96 ± 0.88	1.69 ± 0.76	P<0.001
Lathosterol/TC ratio, µg/mg	0.76 ± 0.17	1.12 ± 0.08	1.43 ± 0.10	1.98 ± 0.35	P<0.001
Simvastatin 80mg, N=289	N=66	N=74	N=74	N=75	
Change in LDL-C, mmol/l	-3.22 ± 0.97	-3.13 ± 1.73	-3.40 ± 1.38	-3.89 ± 1.49	p=0.593 ^a
Ezetimibe/simvastatin 10/80mg, N=302	N=82	N=73	N=74	N=73	
Change in LDL-C, mmol/l	-4.42 ± 1.36	-4.83 ± 1.27	-4.88 ± 1.39	-5.20 ± 1.60	p=0.136 ^a

Data are presented as mean ± SD, median [range] or number (%) per quartile. P indicates P for linearity between lathosterol/TC quartiles and study parameters.

Associations of quartiles with baseline parameters were evaluated by means of ANOVA.

Associations of quartiles in the different treatment arms were evaluated by means of linear regression, ^a adjusted for baseline LDL-C